[go: nahoru, domu]

Jump to content

Lu 29-252

From Wikipedia, the free encyclopedia

Lu 29-252
Clinical data
Other namesLu-29-252; LU-29252; LU29252; Lu 29–252
Drug classSigma σ2 receptor ligand
Identifiers
  • 1'-(4-spiro[1H-2-benzofuran-3,4'-piperidine]-1'-ylbutyl)spiro[1H-2-benzofuran-3,4'-piperidine]
PubChem CID
PubChem SID
Chemical and physical data
FormulaC28H36N2O2
Molar mass432.608 g·mol−1
3D model (JSmol)
  • C1CN(CCC12C3=CC=CC=C3CO2)CCCCN4CCC5(CC4)C6=CC=CC=C6CO5
  • InChI=1S/C28H36N2O2/c1-3-9-25-23(7-1)21-31-27(25)11-17-29(18-12-27)15-5-6-16-30-19-13-28(14-20-30)26-10-4-2-8-24(26)22-32-28/h1-4,7-10H,5-6,11-22H2
  • Key:AEUZWXWBBOOYMB-UHFFFAOYSA-N

Lu 29-252 is a selective sigma σ2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed.[1][2][3][4][5] It reached the preclinical stage of development prior to the discontinuation of its development.[1] The drug was under development by Lundbeck.[1]

References

[edit]
  1. ^ a b c "LU 29252". AdisInsight. Springer Nature Switzerland AG. 23 May 1995. Retrieved 22 October 2024.
  2. ^ "LU-29252". Therapeutic Target Database (TTD). D0T8HU. Retrieved 22 October 2024.
  3. ^ Gronier B, Debonnel G (March 1999). "Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems". European Journal of Pharmacology. 368 (2–3): 183–196. doi:10.1016/s0014-2999(99)00025-4. PMID 10193654.
  4. ^ Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2). Pleiades Publishing Ltd: 83–91. doi:10.1134/s1819712411010028. ISSN 1819-7124.
  5. ^ Rousseaux CG, Greene SF (August 2016). "Sigma receptors [σRs]: biology in normal and diseased states". Journal of Receptor and Signal Transduction Research. 36 (4): 327–388. doi:10.3109/10799893.2015.1015737. PMC 4906365. PMID 26056947.